ZNTL Zentalis Pharmaceuticals Inc
Price (delayed)
$1.355
Market cap
$97.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.33
Enterprise value
$100.35M
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of
Highlights
Zentalis Pharmaceuticals's EPS has increased by 48% YoY and by 6% from the previous quarter
Zentalis Pharmaceuticals's net income has increased by 43% YoY and by 7% from the previous quarter
The revenue has dropped by 100% since the previous quarter
ZNTL's gross profit has shrunk by 100% QoQ
Key stats
What are the main financial stats of ZNTL
Market
Valuations
Earnings
Shares outstanding
71.81M
Market cap
$97.3M
Enterprise value
$100.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.29
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$258.62M
Net income
-$165.84M
EBIT
-$165.66M
EBITDA
-$164.37M
Free cash flow
-$171.02M
Per share
Balance sheet
Liquidity
EPS
-$2.33
EPS diluted
-$2.33
Free cash flow per share
-$2.41
Book value per share
$4.73
Revenue per share
$0
TBVPS
$6.05
Total assets
$430.34M
Total liabilities
$93.15M
Debt
$39.58M
Equity
$337.19M
Working capital
$333.34M
Debt to equity
0.12
Current ratio
7.32
Quick ratio
7.18
Net debt/EBITDA
-0.02
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-34.4%
Return on equity
-43.3%
Return on invested capital
-39.1%
Return on capital employed
-43.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZNTL stock price
How has the Zentalis Pharmaceuticals stock price performed over time
Intraday
-2.52%
1 week
-23.01%
1 month
-34.54%
1 year
-90.61%
YTD
-55.28%
QTD
-14.78%
Financial performance
How have Zentalis Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$258.62M
Net income
-$165.84M
Gross margin
N/A
Net margin
N/A
The revenue has dropped by 100% since the previous quarter
ZNTL's gross profit has shrunk by 100% QoQ
Zentalis Pharmaceuticals's net income has increased by 43% YoY and by 7% from the previous quarter
The operating income has contracted by 24% from the previous quarter but it has grown by 14% YoY
Growth
What is Zentalis Pharmaceuticals's growth rate over time
Valuation
What is Zentalis Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.29
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Zentalis Pharmaceuticals's EPS has increased by 48% YoY and by 6% from the previous quarter
The P/B is 93% less than the 5-year quarterly average of 4.4 and 74% less than the last 4 quarters average of 1.1
ZNTL's equity is down by 23% YoY and by 4.8% from the previous quarter
The revenue has dropped by 100% since the previous quarter
Efficiency
How efficient is Zentalis Pharmaceuticals business performance
ZNTL's ROIC is up by 43% year-on-year
The ROA is up by 34% year-on-year
The ROE rose by 32% year-on-year
Dividends
What is ZNTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZNTL.
Financial health
How did Zentalis Pharmaceuticals financials performed over time
The total assets has contracted by 22% YoY and by 4.5% from the previous quarter
The total liabilities has declined by 19% year-on-year and by 3.3% since the previous quarter
The company's debt is 88% lower than its equity
ZNTL's equity is down by 23% YoY and by 4.8% from the previous quarter
The debt to equity has grown by 20% year-on-year and by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.